Edgardo Santos, MD, FACP
Articles
An Overview of Trilaciclib Safety and Patient QOL Outcomes
July 22, 2022
Video
Focusing the discussion on the clinical trials that led to the FDA approval of trilaciclib, experts in ES-SCLC share key insights into the drug’s safety and its effect on patient quality of life.
Unmet Needs and Future Directions in the Management of CIM
July 22, 2022
Video
Martin Dietrich, MD, PhD, and Edgardo Santos, MD, FACP, offer closing remarks on unmet needs and future directions in the management of CIM including other disease states where trilaciclib may offer myeloprotective benefit.
Myeloprotective Benefit of CDK4/6 Inhibition in ES-SCLC
July 15, 2022
Video
Edgardo Santos, MD, FACP, and Martin Dietrich, MD, PhD, share insights into the mechanism of action of CDK4/6 inhibitors for the prevention of myelosuppression in ES-SCLC.
Trilaciclib Efficacy in the Prevention of CIM in ES-SCLC
July 15, 2022
Video
Renowned leaders in thoracic oncology discuss efficacy data from key clinical trials that led to the FDA approval of the CDK4/6 inhibitor trilaciclib for CIM prophylaxis in ES-SCLC, including the drug’s role in later treatment lines.
An Overview of Chemotherapy-Induced Myelosuppression in ES-SCLC
July 08, 2022
Video
Two leaders in the management of ES-SCLC provide an overview of chemotherapy-induced myelosuppression including key risk factors and its effect on patient outcomes.
Prophylactic Approaches to the Management of CIM in ES-SCLC
July 08, 2022
Video
Expert panelists review considerations in the prophylactic treatment of chemotherapy-induced myelosuppression with special attention paid to unmet needs related to the use of G-CSF and ESAs.